News Corp Axes ‘The Daily’, Originally an Apple Inc. (AAPL) iPad Exclusive

Page 1 of 2

Apple Inc. (NASDAQ:AAPL)‘s iPad currently has over 275,000 apps available in its App Store, ranging from business news to video games, but one of the most innovative was a publication introduced by News Corp (NASDAQ:NWSA) in early 2011. Called “The Daily,” News Corp’s tablet-only digital newspaper was centered on the idea that readers would be offered far lower prices than traditional publications charged due to the lack of print infrastructure, while enjoying a streamlined interface designed for touch-screen technology.

Apple Inc. (NASDAQ:AAPL)

In a press release on its official website today, though, News Corp is announcing that it “will cease standalone publication of The Daily iPad app on December 15, 2012,” and that some pieces of its structure “will be folded into The [New York] Post.” On the decision, CEO Rupert Murdoch had this to say:

“From its launch, The Daily was a bold experiment in digital publishing and an amazing vehicle for innovation. Unfortunately, our experience was that we could not find a large enough audience quickly enough to convince us the business model was sustainable in the long-term. Therefore we will take the very best of what we have learned at The Daily and apply it to all our properties. […] I know The New York Post will continue to grow and become stronger on the web, on mobile, and not least, the paper itself.”

While the publication was originally launched as a standalone app for Apple Inc. (NASDAQ:AAPL)’s iPad, versions for the iPhone, Google Inc (NASDAQ:GOOG) Android tablets, and the, Inc. (NASDAQ:AMZN) Kindle Fire had been added more recently, along with a pricing structure that was available on a weekly, monthly, or yearly basis. Regarding Apple’s iPad, readers could subscribe for 99 cents a week or $39.99 a year, while iPhone and Kindle versions were offered at close to half this price.

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!